News >

Despite Progress With CAR T-Cell Therapy, Transplant Retains Role in Myeloma

Caroline Seymour
Published: Thursday, Jan 03, 2019

Deepu Madduri, MD

Deepu Madduri, MD

The influx of novel therapies into the multiple myeloma treatment armamentarium continues to challenge the role of transplant; however, Deepu Madduri, MD, explained that this approach is still recommended for eligible patients, as much remains unknown with chimeric antigen receptor (CAR) T-cell therapy.

“If we feel that a patient is transplant-eligible, even if they do not necessarily want to do a transplant at that time, it’s important to harvest their stem cells and store them for the future, because you never know when you may need them,” said Madduri, an assistant professor at Mount Sinai Hospital.

In terms of CAR T-cell therapy, the next-generation B-cell maturation antigen (BCMA)-targeted product, bb21217, an enhanced version of bb2121, showed preliminary efficacy in results reported at the 2018 ASH Annual Meeting. Data showed that the objective response rate was 83.3% and the very good partial response or better rate was 75% in heavily pretreated patients with relapsed/refractory disease.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication